+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 26 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating the best way to combine chemotherapy and radiation therapy for children and young adults with localized non-germinomatous germ cell tumors NGGCT in the brain. The study aims to optimize radiation treatment for patients who respond well to initial chemotherapy and to use higher dose chemotherapy followed by radiation for those who do not respond as well. This phase II trial focuses on how tumors respond to initial chemotherapy to decide the next treatment steps, aiming to reduce side effects and improve disease control. Participants receive induction chemotherapy with drugs like carboplatin, etoposide, ifosfamide, and thiotepa over up to six cycles, repeated every 21 days if no disease progression occurs. Based on their response, patients are assigned to one of two plans Plan A involves radiation therapy to the ventricles and spinal canal WVSCI, while Plan B includes high-dose chemotherapy with stem cell transplant followed by craniospinal radiation. Some patients may undergo second-look surgery to guide treatment decisions. During the study, participants have MRIs, cerebrospinal fluid and blood samples collected, and complete questionnaires assessing cognitive and behavioral functions. Researchers monitor tumor response, progression-free survival, overall survival, and side effects over up to 10 years. The study also compares outcomes based on radiation type and its effects on growth and blood counts, aiming to improve long-term quality of life for patients.

Age: 3Years - 29YearsAll GendersPhase 2
170 locations
E

Actively Recruiting

Researchers are evaluating combination chemotherapy treatments for patients with newly diagnosed diffuse anaplastic Wilms tumors DAWT and relapsed favorable histology Wilms tumors FHWT. This phase II trial aims to compare different chemotherapy regimens to see if adding drugs like vincristine and irinotecan improves survival outcomes for these patients, based on historical data. The study also explores kidney toxicity, genetic factors, and surgical outcomes related to these tumors. Patients are assigned to one of two treatment groups. Arm I Regimen UH-3 involves multiple cycles of vincristine, doxorubicin, cyclophosphamide, carboplatin, etoposide, and irinotecan administered intravenously every 21 days with radiation therapy as needed. Arm II Regimen ICECycloTopo includes cycles of carboplatin, etoposide, ifosfamide, cyclophosphamide, and topotecan given intravenously every 21 days with surgery andor radiation as clinically indicated. Both groups undergo various imaging scans and biopsies throughout treatment. Participants are closely monitored with CT, PET, X-rays, MRI, ultrasound, bone scans, blood tests, and biopsies during the trial. After treatment, follow-up visits occur every 3 months for the first two years, then every 6 months for years 3 and 4, and once at year 5. The primary outcomes measured are event-free survival and overall survival up to five years. The study also collects blood, urine, and tumor tissue samples for future research and monitors treatment side effects and kidney function.

Age: 0 - 30YearsAll GendersPhase 2
205 locations
E

Actively Recruiting

Researchers are evaluating how well a lower dose of radiotherapy after chemotherapy works to treat children and young adults with central nervous system CNS germinomas. This Phase II study focuses on using carboplatin and etoposide chemotherapy followed by reduced radiation doses to see if this approach can effectively control the disease while potentially reducing long-term side effects. The study also investigates neuroendocrine function and cognitive processing speed as important outcomes. Participants receive up to four cycles of chemotherapy with carboplatin given intravenously on day 1 and etoposide given intravenously on days 1 through 3 every 21 days. After chemotherapy, patients are assigned to different treatment groups based on their response and tumor characteristics. Radiation therapy options include 3-dimensional conformal radiation, intensity-modulated radiation, or proton therapy with varying doses depending on the specific group. Some patients may undergo second-look surgery to assess tumor response. Blood, cerebrospinal fluid, and tissue samples may be collected throughout the study for further research. During the study, participants undergo regular magnetic resonance imaging MRI scans and may have lumbar punctures for cerebrospinal fluid collection during screening and follow-up. They are monitored for event-free survival, overall survival, tumor response, neuroendocrine function, and cognitive processing speed over several years. Follow-up visits occur every 3 months for the first year, then every 4 months for two years, followed by annual visits for up to 10 years after treatment. This allows researchers to assess long-term effects and outcomes.

Age: 3Years - 29YearsAll GendersPhase 2
115 locations
P

Actively Recruiting

Researchers are evaluating treatments for children and young adults with low-risk and average-risk medulloblastoma, a type of brain cancer. This phase III trial aims to test two main ideas whether adding sodium thiosulfate STS to standard chemotherapy and radiation can reduce hearing loss caused by cisplatin in average-risk patients, and whether a less intense radiation therapy can be as effective for low-risk patients while reducing side effects. The study also compares outcomes to previous treatments to ensure survival and recurrence rates are not negatively affected. Participants receive radiation therapy daily for 6 weeks and weekly vincristine during treatment weeks. Maintenance therapy begins about 4 weeks later and includes cycles of oral lomustine, intravenous cisplatin, intravenous sodium thiosulfate, cyclophosphamide, and vincristine given on specific days and cycles over several months. Patients undergo MRI scans and cerebrospinal fluid collections throughout the study, with optional blood samples. After treatment, follow-up visits occur regularly for up to 10 years. Throughout the study, participants have hearing tests, brain scans, and lab tests to monitor effects and side effects. Researchers assess hearing loss, event-free and overall survival, kidney function, neurocognitive outcomes, quality of life, and social factors. Hearing loss is evaluated shortly after treatment and over time. This long-term monitoring helps understand the safety and impact of the treatments, with total involvement lasting up to 10 years after starting therapy.

Age: 4Years - 21YearsAll GendersPhase 3
111 locations
I

Actively Recruiting

Researchers are evaluating the combination of blinatumomab with dasatinib or imatinib and standard chemotherapy to treat children, adolescents, and young adults with Philadelphia chromosome positive Ph or ABL-class Philadelphia chromosome-like Ph-like B-cell acute lymphoblastic leukemia B-ALL. This phase 2 trial aims to estimate event-free survival, overall survival, and safety profiles, including infections and neurotoxicity, over three years in these patients. The study also explores minimal residual disease negativity, immune function, and drug levels in the plasma and cerebrospinal fluid to better understand treatment response and outcomes. Participants receive a complex treatment plan based on their leukemia subtype. Those with Ph B-ALL receive a modified chemotherapy backbone combined with dasatinib and three cycles of blinatumomab, while patients with ABL-class Ph-like B-ALL receive similar chemotherapy with imatinib or dasatinib depending on gene fusion type. Treatment includes multiple phases such as induction, blinatumomab blocks, interim maintenance, delayed intensification, and maintenance cycles over about two years. Additional therapies like radiation, intrathecal methotrexate, and various chemotherapy drugs are also given as part of the regimen. Throughout the study, participants undergo regular evaluations including echocardiography or multigated acquisition scans during screening, as well as blood and cerebrospinal fluid collection and bone marrow biopsies at various points. Researchers closely monitor disease status, adverse events, and minimal residual disease using advanced tests. The primary outcomes measure event-free survival and adverse events up to three years, with secondary outcomes including overall survival and relapse rates. Participants remain under observation for safety and treatment response during the entire course of therapy.

Age: 366Days - 46YearsAll GendersPhase 2
161 locations
C

Actively Recruiting

Researchers are evaluating the effects of nivolumab combined with blinatumomab compared to blinatumomab alone in patients with first relapse B-cell acute lymphoblastic leukemia B-ALL, including those with Down syndrome. This phase II trial aims to assess event-free survival and safety in children and young adults aged 1 to under 31 years. The study also explores remission rates and adverse events related to these treatments. Participants receive different combinations of blinatumomab, nivolumab, dexamethasone, methotrexate, and other chemotherapy drugs depending on their assigned group or arm. Treatment cycles generally last 36 to 37 days and may repeat up to two cycles if no disease progression or unacceptable toxicity occurs. Additional therapies like radiation and intrathecal chemotherapy are given based on disease characteristics. Down syndrome patients have a specific treatment arm with tailored medication schedules. Throughout the study, participants undergo lumbar punctures, bone marrow biopsies and aspirations, and collection of blood, urine, and cerebrospinal fluid for monitoring. Follow-up visits occur every three months for one year after treatment completion to assess outcomes such as minimal residual disease negative remission and event-free survival. Safety and tolerability are closely monitored during therapy and follow-up.

Age: 1Year - 30YearsAll GendersPhase 2
227 locations
C

Actively Recruiting

Researchers are investigating treatments for newly diagnosed acute myeloid leukemia AML in children and young adults, with or without mutations in the FLT3 gene. This Phase III trial compares standard chemotherapy, which includes daunorubicin, cytarabine, and gemtuzumab ozogamicin, to therapy using a special formulation called CPX-351, which contains daunorubicin and cytarabine designed to stay longer in the bone marrow. The study also evaluates adding gilteritinib, a drug that may block abnormal FLT3 gene function and slow cancer growth, especially in patients with FLT3 mutations. The goals include comparing treatment effects, studying heart function during therapy, and assessing neurocognitive outcomes. Participants receive treatment based on risk groups and FLT3 mutation status, assigned to different study arms. Treatments include various combinations of chemotherapy drugs given intravenously, intrathecally, or orally, such as CPX-351, daunorubicin, cytarabine, gemtuzumab ozogamicin, dexrazoxane, etoposide, mitoxantrone, and gilteritinib. Treatment phases include induction, intensification, and for some, hematopoietic stem cell transplantation HSCT. Intrathecal therapies address central nervous system involvement. Gilteritinib is administered orally over extended periods in certain groups. The study also involves optional neurocognitive testing. Throughout the study, participants undergo regular assessments including blood and bone marrow samples, imaging scans like MRI and PET, and cardiac function tests such as echocardiograms. Researchers monitor minimal residual disease, survival rates, heart health, and neuropsychological function. Safety and adverse events are tracked up to three years, with some patients receiving long-term gilteritinib maintenance. The overall participation may last several years, allowing detailed evaluation of treatment impact and side effects.

Age: 6Months - 21YearsAll GendersPhase 3
206 locations
C

Actively Recruiting

Researchers are comparing the effects of adding immunotherapy drugs, brentuximab vedotin and nivolumab, to the standard chemotherapy treatment, with or without radiation, for patients diagnosed with early stage classical Hodgkin lymphoma stage I or II. This phase III trial aims to evaluate whether this combination improves survival and reduces side effects compared to standard treatment alone. The study includes both children and adults aged 5 to 60 years with newly diagnosed disease and measurable tumors. Participants first receive two cycles of the ABVD chemotherapy regimen. After treatment, imaging scans determine their early response, classifying them as rapid or slow responders and stratifying them by risk status favorable or unfavorable. Based on these factors, patients are assigned to one of eight different treatment arms involving variations of chemotherapy, immunotherapy, and involved-site radiation therapy. Treatments are given in cycles every 28 days, with some arms receiving additional cycles or radiation depending on response and risk. Throughout the trial, participants undergo regular imaging tests such as PET, CT, or MRI scans to monitor disease and treatment effects. Blood samples may also be collected. Following treatment completion, patients will be followed up with visits every 3 months for the first year, then every 6 months for two years, and annually up to 12 years. Researchers will assess outcomes including progression-free survival, overall survival, adverse events, patient-reported quality of life, fatigue, cognitive function, and long-term side effects.

Age: 5Years - 60YearsAll GendersPhase 3
419 locations
P

Actively Recruiting

Researchers are comparing the effects of two treatment combinations in adults with stage IV or recurrent non-squamous non-small cell lung cancer NSCLC that has a PD-L1 expression of 1% or higher. This phase 3 trial investigates whether Nivolumab and Relatlimab combined with chemotherapy works differently than Pembrolizumab with chemotherapy as first-line treatment for this condition. The study is sponsored by Bristol-Myers Squibb and uses a randomized parallel design. Participants will be assigned to one of two groups one group receives Nivolumab and Relatlimab with chemotherapy drugs, while the other group receives Pembrolizumab with chemotherapy. Chemotherapy may include drugs such as Carboplatin, Pemetrexed, or Cisplatin, given at specified doses on specific days. Treatment schedules and doses are carefully planned, and participants are treated during the trial period. During the study, participants undergo regular assessments to measure overall survival, progression-free survival, response rates, and duration of response, with follow-up lasting up to five years. Researchers also track adverse events and immune-related side effects for up to 2.5 years. Quality of life is monitored through symptom questionnaires. Assessments include imaging scans and laboratory tests to evaluate disease status and treatment effects. The total duration of participation may extend over several years to capture long-term outcomes and safety.

Age: 18Years +All GendersPhase 3
329 locations
E

Actively Recruiting

This research aims to evaluate the safety, side effects, optimal dose, and effectiveness of tovorafenib DAY101 in treating children and young adults with progressive, relapsed, or refractory Langerhans cell histiocytosis LCH. LCH is a condition where too many immature white blood cells called Langerhans cells build up and form tumors that can damage bones, skin, lungs, and the pituitary gland. This disease occurs more often in children and young adults, and the study focuses on those with relapsed or refractory LCH, including those with specific genetic mutations. Participants receive tovorafenib orally once a week on days 1, 8, 15, and 22 of each 28-day cycle. Treatment continues for up to 12 cycles unless the disease worsens or side effects become unacceptable. During the study, participants undergo various scans such as echocardiography ECHO or multigated acquisition MUGA, and imaging with FDG-PET or CT to monitor the disease. Blood and urine samples are collected regularly. If bone marrow or central nervous system involvement is suspected, participants may also have bone marrow biopsies and lumbar punctures. Throughout the trial, researchers assess response to treatment, side effects, event-free survival, and overall survival up to two years. After treatment, participants are followed up at 28 days, then at 3, 6, 9, and 12 months, and again at two years post-treatment. The study includes monitoring of bone marrow and blood for genetic mutations and disease markers. This comprehensive approach helps evaluate tovorafenibs impact on relapsed or refractory LCH over time.

Age: 180Days - 22YearsAll GendersPhase 2
123 locations

1-10 of 26

1